What is the effect on cardiovascular events of reducing hyperuricemia with allopurinol?;Qual o efeito da redução da hiperuricemia nos eventos cardiovasculares? Revisão baseada na evidência

Revista Portuguesa de Cardiologia

Volumn 33, Issue 11, 2014, Pages 727-732

  Guedes, Marta ^a   Esperança, Ana ^a   Pereira, Ana Cristina ^b   Rego, Catarina ^a  

^a ACeS Espinho Gaia   (Portugal)

^b Agrupamento de Centros de Saúde do Alto Ave   (Portugal)

Author keywords

Allopurinol; Cardiovasculardisease; Uric acid

Indexed keywords

ALLOPURINOL; ENZYME INHIBITOR;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; DRUG MEGADOSE; GOUT; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; HYPERURICEMIA; META ANALYSIS (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); THERAPY EFFECT; CARDIOVASCULAR DISEASES; COMPLICATION;

ALLOPURINOL; CARDIOVASCULAR DISEASES; ENZYME INHIBITORS; HUMANS; HYPERURICEMIA;

EID: 84918813873     PISSN: 08702551     EISSN: 21742030     Source Type: Journal    
DOI: 10.1016/j.repc.2014.06.002     Document Type: Article

References (12)

1. Becker, MA. Asymptomatic hyperuricemia. Literature review current through: Jan 2012. [página na Internet; acedida 8 Jan 2014]. Disponível em: www.uptodate.com
2. H.E. Dincer, P.D. Dincer, and D.J. Levinson Asymptomatic hyperuricemia: to treat or not to treat Cleve Clin J Med. 69 597 2002 600 602
3. Becker, MA. Uric acid balance. Literature review current through: Mar 2012 [página na Internet; acedida 8 Jan 2014]. Disponível em: www.uptodate.com
4. J.F. Baker, L. Chen, and H.R. Schumacher Serum acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med. 118 2005 816 826
5. Portugal. Programa Nacional para as Doenças Cerebro-Cardiovasculares. Orientações Programáticas. DGS; 2012 [acedida 8 Jan 2014]. Disponível em www.dgs.pt
6. M. Goicoechea, S.G. de Vinuesa, and U. Verdalles Effect of allopurinol in chronic kidney disease progression and cardiovascular risk Clin J Am Soc Nephrol. 5 2010 1388 1393
7. A.D. Struthers, P.T. Donnan, and P. Lindsay Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study Heart. 87 2002 229 234
8. L. Wei, I.S. Mackenzie, and Y. Chen Impact of allopurinol use on urate concentration and cardiovascular outcome Br J Clin Pharmacol. 71 2011 600 607
9. L. Wei, T. Fahey, and A.D. Struthers Association between allopurinol and mortality in heart failure patients: a long-term follow-up study Int J Clin Pract. 63 2009 1327 1333
10. G. Thanassoulis, J.M. Brophy, and H. Richard Gout, allopurinol use, and heart failure outcomes Arch Intern Med. 170 2010 1358 1364
11. J.J. McMurray, S. Adamopoulos, and S.D. Anker ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur Heart J. 33 2012 1787 1847
12. G. Montalescot, U. Sechtem, and S. Achenbach 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology Eur Heart J. 34 2013 2949 3003